DAGOBERTO CALLEGARO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/62 - Laboratório de Fisiopatologia Cirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/62 - Laboratório de Fisiopatologia Cirúrgica, Hospital das Clínicas, Faculdade de Medicina
18 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 18
- Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks(2014) SATO, Douglas Kazutoshi; CALLEGARO, Dagoberto; JORGE, Frederico M. de Haidar; NAKASHIMA, Ichiro; NISHIYAMA, Shuhei; TAKAHASHI, Toshiyuki; SIMM, Renata Faria; APOSTOLOS-PEREIRA, Samira Luisa; MISU, Tatsuro; STEINMAN, Lawrence; AOKI, Masashi; FUJIHARA, KazuoTo elucidate immunopathogenetic roles of aquaporin-4 antibodies in the cerebrospinal fluid (CSF) of neuromyelitis optica spectrum disorders (NMOSD), we analyzed aquaporin-4 antibody titers, cellular and inflammatory markers in the CSF collected from 11 aquaporin-4 antibody seropositive patients. The CSF aquaporin-4 antibody levels during attacks (but not in sera) closely correlated with pleocytosis, inflammatory cytokines including interleukin-6 that can regulate antibody-producing plasmablasts, and glial fibrillary acidic protein levels in the CSF. The amount of aquaporin-4 antibodies present in the central nervous system may have therapeutic implications, as it is associated with astrocyte injury and inflammatory responses during NMOSD attacks.
conferenceObject Non-organ-specific auto-immunity disease in NMO-spectrum disorders - Brazilian experience(2012) APOSTOLOS-PEREIRA, S.; JORGE, F.; ZAGO, P.; SIMM, R.; FAZZITO, M.; GALVAO, C.; HOBI, C.; LANA-PEIXOTO, M.; MARCHIORI, P.; DELLAVANCE, A.; CALLEGARO, D.conferenceObject Clinically suspected neuromyelitis optica associated to anti-MOG antibodies(2015) SALLES, L. M. O. de Paula; SATO, D. K.; APOATOLOS-PEREIRA, S. L.; SIMM, R. F.; JORGE, F. M. H.; FUJIHARA, K.; CALLEGARO, D.conferenceObject Evaluation of treatment response to plasmapheresis in acute exacerbations of neuromyelitis optica(2014) LINHARES, G. E. S.; PEREIRA, S. L. A.; JORGE, F. M. H.; SIMM, R.; OLIVEIRA, L. M.; MENDES, L. S.; CALLEGARO, D.conferenceObject Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies(2013) SATO, D.; JORGE, F.; LANA-PEIXOTO, M. A.; WATERS, P.; NAKASHIMA, I.; PEREIRA, S. Apostolos; TALIM, N.; TAKAHASHI, T.; ZAGO, P.; LEITE, M. I.; BOSSO, K.; SIMM, R.; MISU, T.; AOKI, M.; FUJIHARA, K.; CALLEGARO, D.conferenceObject Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks(2015) SATO, D. K.; CALLEGARO, D.; JORGE, F. M. H.; NAKASHIMA, I.; NISHIYAMA, S.; TAKAHASHI, T.; SIMM, R. F.; APOSTOLOS-PEREIRA, S. L.; MISU, T.; STEINMAN, L.; AOKI, M.; FUJIHARA, K.conferenceObject Neuromyelitis optica previously diagnosed as multiple sclerosis(2012) MELO, P. Zago; JORGE, F.; SIMM, R. Faria; PEREIRA, S. Apostolos; GALVAO, C.; HOBI, C.; MORAES, L.; FAZZITO, M.; SATO, D.; LANA-PEIXOTO, M.; CALLEGARO, D.- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders(2014) SATO, Douglas Kazutoshi; CALLEGARO, Dagoberto; LANA-PEIXOTO, Marco Aurelio; WATERS, Patrick J.; JORGE, Frederico M. de Haidar; TAKAHASHI, Toshiyuki; NAKASHIMA, Ichiro; APOSTOLOS-PEREIRA, Samira Luisa; TALIM, Natalia; SIMM, Renata Faria; LINO, Angelina Maria Martins; MISU, Tatsuro; LEITE, Maria Isabel; AOKI, Masashi; FUJIHARA, KazuoObjective:To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies.Methods:Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested for MOG and AQP4 antibodies using cell-based assays with live transfected cells.Results:Among the 215 patients with NMOSD, 7.4% (16/215) were positive for MOG antibodies and 64.7% (139/215) were positive for AQP4 antibodies. No patients were positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) of the patients negative for AQP4 antibodies. Compared with patients with AQP4 antibodies or patients who were seronegative, patients with MOG antibodies were more frequently male, had a more restricted phenotype (optic nerve more than spinal cord), more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had spinal cord lesions distributed in the lower portion of the spinal cord, and usually demonstrated better functional recovery after an attack.Conclusions:Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.
- Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis(2018) MARQUES, Vanessa Daccach; PASSOS, Giordani Rodrigues dos; MENDES, Maria Fernando; CALLEGARO, Dagoberto; LANA-PEIXOTO, Marco Aurelio; COMINI-FROTA, Elizabeth Regina; VASCONCELOS, Claudia Cristina Ferreira; SATO, Douglas Kazutoshi; FERREIRA, Maria Lucia Brito; PAROLIN, Monica Koncke Fiuza; DAMASCENO, Alfredo; GRZESIUK, Anderson Kuntz; MUNIZ, Andre; MATTA, Andre Palma da Cunha; OLIVEIRA, Bianca Etelvina Santos de; TAUI, Carlos Bernardo; MACIEL, Damacio Ramon Kaimen; DINIZ, Denise Sisteroli; CORREA, Eber Castro; CORONETTI, Fernando; JORGE, Frederico M. H.; SATO, Henry Koiti; GONCALVES, Marcus Vinicius Magno; SOUSA, Nise Alessandra de C.; NOSCIMENTO, Osvaldo J. M.; GAMA, Paulo Diniz da; DOMINGUES, Renan; SIMM, Renato Faria; THOMAZ, Rodrigo Barbosa; MORALES, Rogerio de Rizo; DIAS, Ronaldo Maciel; APOSTOLOS-PEREIRA, Samira dos; MACHADO, Suzana Costa Nunes; JUNQUEIRA, Thiago de Faria; BECKER, JeffersonThe expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.
conferenceObject Autoantibodies against MOG and aquaporin-4 identify distinct neuromyelitis optica spectrum disorders subgroups(2014) SATO, D. K.; CALLEGARO, D.; LANA-PEIXOTO, M. A.; WATERS, P. J.; TANAKA, S.; JORGE, F. M. H.; TAKAHASHI, T.; MISU, T.; APOSTOLOS-PEREIRA, S. L.; TALIM, N.; SIMM, R. F.; NAKASHIMA, I.; NOMURA, K.; AOKI, M.; FUJIHARA, K.